Showing results (141-150 of 369) with videos related to

Sort By:
Pageof 37
Transfusion Medicine (Oxford, England)|December 1, 1995
A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern IrelandC A Ludlam, G D Lowe, E E Mayne
The British Journal of Ophthalmology|January 1, 1995
Influence of age, systemic blood pressure, smoking, and blood viscosity on orbital blood velocitiesT H Williamson, G D Lowe, G M Baxter
Postgraduate Medical Journal|January 1, 1979
Fatal retroperitoneal haemorrhage complicating anticoagulant therapyG D Lowe, J H McKillop, A G Prentice
Scottish Medical Journal|July 31, 1998
Heart and arterial disease risk factors measured in an office workforce: changes from 1993 to 1996. The Scottish Heart and Arterial Risk Prevention Group (SHARP)S R McEwan, C Hau, F Daly, et al.
Urological Research|November 10, 1976
The incidence of deep vein thrombosis in prostatectomised patients following the administration of the fibrinolytic inhibitor, aminocaproic acid (EACA)J Sinclair, C D Forbes, C R Prentice, et al.
Arthritis and Rheumatism|September 1, 1988
Mechanisms of joint damage in an experimental model of hemophilic arthritisR Madhok, D Bennett, R D Sturrock, et al.
The International Journal of Artificial Organs|November 1, 1991
Modification of the influence of biomaterials on contact activationS Sundaram, L Irvine, J M Courtney, et al.
British Journal of Haematology|March 2, 1999
Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular diseaseM Woodward, A Rumley, H Tunstall-Pedoe, et al.
European Heart Journal|March 21, 1998
Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health StudyM Woodward, G D Lowe, A Rumley, et al.
Diabetes Care|October 1, 1989
Tissue plasminogen activator inhibition in diabetes mellitusM Small, C Kluft, A C MacCuish, et al.
Pageof 37